Case Report: Deep and durable response to talazoparib in germline BRCA2-mutated rectal neuroendocrine carcinoma

High-grade neuroendocrine carcinoma (NEC) of the rectum is a rare and aggressive malignancy, with limited treatment options and a poor prognosis. We report the successful off-label use of the PARP inhibitor talazoparib in a patient with metastatic, germline BRCA2-mutated rectal NEC who had a contrai...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Milan Khealani, Byoung Uk Park, Robben Schat, Emmanuel S. Antonarakis, Arjun Gupta
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2025-12-01
סדרה:	Frontiers in Oncology
נושאים:	rectal neuroendocrine carcinoma gBRCA2 mutation talazoparib PARP inhibitor case report
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1705579/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!